Hanmi Pharm Establishes 'Open Innovation Center' in Basel, Switzerland, Europe's Largest Bio Cluster

Swiss Basel Innovation Park.
Photo by Hanmi Pharm.

[Asia Economy Reporter Lee Gwan-joo] Hanmi Pharmaceutical announced on the 31st that it has established an open innovation center at the Switzerland Innovation Park, the largest bio cluster in Europe located in Basel, Switzerland. This is the second base after securing a foothold at the CIC (Cambridge Innovation Center) in Boston, USA in 2020.

Basel, Switzerland, is the largest bio cluster in Europe, home to global pharmaceutical and biotech companies such as Roche, Johnson & Johnson, Bayer, and Lonza, as well as over 700 life sciences and biotech companies. More than 31,000 industry-academia researchers in Basel are conducting leading research across various therapeutic areas. The company explained that the concentrated infrastructure has created a robust bio healthcare ecosystem, making it an optimal strategic location as a foothold for entry into the European market.

Hanmi Pharmaceutical plans to expand its network and cooperation with advanced pharmaceutical and biotech companies based on its two hubs leading global open innovation in Europe and the United States, and to more aggressively promote technology export and import. Since Hanmi Pharmaceutical has annually presented its own pipeline research results at major international conferences such as the European Society for Medical Oncology (ESMO), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of the Liver (EASL), it expects that securing this European base will enable active formation of a global network.

Hanmi Pharmaceutical President Kwon Se-chang said, "It is meaningful to establish a global expansion base in Basel, Switzerland, where next-generation drug development is taking place," adding, "We will strive to build collaboration models with innovative bio companies in this bio cluster to lead the development of treatments for diseases with unmet medical needs, as well as next-generation cancer and rare disease therapies."

This content was produced with the assistance of AI translation services.